张巍巍, 管同 . 基因治疗浪潮下中国血友病治疗的范式转移与启示[J]. 科技导报, 0 : 1 . DOI: 10.3981/j.issn.1000-7857.2024.01.00057

[1] National Academies of Sciences E. Human genome editing: Science, ethics, and governance[M]. Washington, DC:The National Academies Press, 2017.

[2] Vokinger K N, Glaus C E G, Kesselheim A S. Approval and therapeutic value of gene therapies in the US and Eu⁃rope[J]. Gene Therapy, 2023, 30(10-11): 756-760.

[3]. Gene therapy needs a long-term approach[J]. Nature Medicine, 2021, 27(4): 563.

[4] Samelson-Jones B J, Finn J D, George L A, et al. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity[J]. JCI Insight, 2019, 5(14): 128683.

[5] Pipe S W, Arruda V R, Lange C, et al. Characteristics of BAY 2599023 in the current treatment landscape of hemophilia A gene therapy[J]. Current Gene Therapy, 2023,23(2): 81-95.

[6] Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: Diagnosis, treatments, and its complications[J]. The Lancet, 2016, 388(10040): 187-197.

[7] Mancuso M E, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates[J]. Journal of Clinical Medicine, 2017, 6(4): 39.

[8] Keam S J. Efanesoctocog Alfa: First approval[J]. Drugs,2023, 83(7): 633-638.

[9] Malec L M, Witmer C M, Jaffray J, et al. Real world use of extended half-life products and the impact on bleeding events and joint health in the United States[J]. Blood,2018, 132(Supplement 1): 1195.

[10] Chhabra A, Spurden D, Fogarty P F, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B[J]. Blood Coagulation and Fibrinolysis, 2020, 31(3): 186-192.

[11] Persson S, Berndt C, Engstrand S, et al. Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A[J]. Haemophilia, 2023, 29(1): 145-155.

[12] Barg A A, Budnik I, Avishai E, et al. Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring[J]. Haemophilia, 2021, 27(3): 383-391.

[13] Xu Y, Wang Y, Wu R H, et al. Emicizumab prophylaxis for the treatment of Chinese hemophilia A patients in the real world: A multi-center retrospective analysis[J].Blood, 2023, 142: 2624.

[14] Batsuli G, Wheeler A P, Weyand A C, et al. Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort[J]. American Journal of Hematology, 2023, 98(10): 285-287.

[15] Mahlangu J, Kaczmarek R, von Drygalski A, et al. Twoyear outcomes of valoctocogene roxaparvovec therapy for hemophilia A[J]. The New England Journal of Medicine,2023, 388(8): 694-705.

[16] Peyvandi F, Mannucci P M, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A[J]. The New England Journal of Medicine,2016, 374(21): 2054-2064.

[17] Fischer K, Lassila R, Peyvandi F, et al. Inhibitor development according to concentrate in severe hemophilia: Reporting on 1392 previously untreated patients from Europe and Canada[J]. Research and Practice in Thrombosis and Haemostasis, 2023, 7(8): 102265.

[18] Schmitt C, Emrich T, Chebon S, et al. Low immunogenicity of emicizumab in persons with haemophilia A[J].Haemophilia, 2021, 27(6): 984-992.

[19] Klamroth R, Hayes G, Andreeva T, et al. Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A[J].Human Gene Therapy, 2022, 33(7/8): 432-441.

[20] Boyce S, James I, Rangarajan S, et al. Seroprevalence to adeno-associated virus type 6 in people with hemophilia B from a UK adult cohort[J]. Research and Practice in Thrombosis and Haemostasis, 2022, 6(4): e12705.

[21] George L A, Monahan P E, Eyster M E, et al. Multiyearfactor VIII expression after AAV gene transfer for hemophilia A[J]. The New England Journal of Medicine,2021, 385(21): 1961-1973.

[22] George L A, Sullivan S K, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant[J]. The New England Journal of Medicine, 2017,377(23): 2215-2227.

[23] Burke T, Asghar S, O'Hara J, et al. Clinical, humanistic,and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: Findings from the CHESS II real-world burden of illness study in Europe[J]. Orphanet Journal of Rare Diseases, 2021, 16(1): 521.

[24] Messori A, Trippoli S. The price of enhanced half-lifefactor IX[J]. Blood Transfusion, 2017, 15(4): 378.

[25] Fujii T, Kidoguchi Y, Takahashi N, et al. Budget impact analysis of Jivi (damoctocog Alfa pegol, Bay 94-9027)in severe hemophilia A in Japan[J]. Journal of Medical Economics, 2021, 24(1): 218-225.

[26] Sun J, Zhao Y, Yang R, et al. The demographics, treatment characteristics and quality of life of adult peoplewith haemophilia in China-results from the HERO study[J]. Haemophilia, 2017, 23(1): 89-97.

[27] Mu Y, Song K M, Song Y. A cross-sectional study of price and affordability of drugs for rare diseases in Shandong Province, China[J]. International Journal of Environmental Research and Public Health, 2022, 19(20):13319.

[28] Naddaf M. Researchers welcome $3.5-million haemophilia gene therapy—But questions remain[J]. Nature,2022, 612: 388-389.

[29] Meier N, Fuchs H, Galactionova K, et al. Cost-effective⁃ness analysis of etranacogene dezaparvovec versus ex⁃tended half-life prophylaxis for moderate-to-severe haemophilia B in Germany[J]. PharmacoEconomics-Open,2024, 8(3): 373-387.

[30] Wang T, Chen E, Regan C, et al. EE706 impact of valoctocogene roxaparvovec on the economic burden of adults with severe hemophilia A managed with prophylaxis in the United States[J]. Value in Health, 2023, 26(12):S190.

[31] Lin Z, Ran X, Liu C, et al. POSC166 cost-effectiveness of emicizumab prophylaxis therapy versus recombinant activated FVII on-demand therapy for hemophilia A with inhibitors in China[J]. Value in Health, 2022, 25(1): S119-S120.

[32] Miesbach W, Chowdary P, Coppens M, et al. Delivery of AAV-based gene therapy through haemophilia centres a need for re-evaluation of infrastructure and comprehensive care: A joint publication of EAHAD and EHC[J]. Haemophilia, 2021, 27(6): 967-973.